Understand the source comparison
Cartalax vs Epithalon: Research Peptide Comparison
Primary Mechanism Cytoprotection via HSP70/HSP90 upregulation in muscle tissue Telomerase activation + pineal gland melatonin modulation Distinct pathways with zero functional overlap Target Tissue Skeletal and cardiac muscle (direct binding) Pineal gland, hyp
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- Cytoprotection via HSP70/HSP90 upregulation in muscle tissue
- Telomerase activation + pineal gland melatonin modulation
- Distinct pathways with zero functional overlap
- Target Tissue
- Skeletal and cardiac muscle (direct binding)
- Pineal gland, hypothalamus, peripheral cells (systemic)
- Cartalax is tissue-specific; Epithalon is neuroendocrine
- Onset of Measurable Effect
- 6–12 hours post-administration in injury models
- 7–14 days for telomerase activity; 4–6 hours for melatonin
- Cartalax suits acute studies; Epithalon requires chronic protocols
- Typical Research Dose Range
- 100–500 µg/kg subcutaneous or intraperitoneal
- 1–10 µg/kg daily for 10–20 day cycles
- Dosing reflects potency differences. Epithalon is 10–50× more potent by weight
- Half-Life
- ~2.5 hours (requires multiple daily doses)
- ~6 hours (single daily dose sufficient)
- Epithalon's longer half-life simplifies protocol compliance
- Evidence Base
- 40+ peer-reviewed studies in cardiovascular and exercise models
- 60+ studies in aging, circadian, and oncology research
- Both are extensively studied but in non-overlapping fields
- Storage Sensitivity
- Moderate (standard −20°C lyophilised, 2–8°C reconstituted)
- High (light-sensitive post-reconstitution; requires amber glass or foil wrap)
- Epithalon degrades faster under improper storage
- Bottom Line
- Use for acute tissue damage, ischemia-reperfusion, muscle recovery studies
- Use for aging research, circadian studies, telomerase-focused protocols
- Selection depends entirely on experimental endpoint. Not 'which is better'